Florence I Raynaud

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7639716/publications.pdf

Version: 2024-02-01

156 papers	12,242 citations	25423 59 h-index	29333 108 g-index
161 all docs	161 docs citations	161 times ranked	18084 citing authors

#	Article	IF	Citations
1	FGF7â€“FGFR2 autocrine signaling increases growth and chemoresistance of fusionâ€positive rhabdomyosarcomas. Molecular Oncology, 2022, 16, 1272-1289.	2.1	7
2	Presence of human breast cancer xenograft changes the diurnal profile of amino acids in mice. Scientific Reports, 2022, 12, 1008.	1.6	3
3	Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo. Journal of Medicinal Chemistry, 2022, 65, 8191-8207.	2.9	5
4	Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 8169-8190.	2.9	13
5	A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2. Science Advances, 2021, 7, .	4.7	8
6	Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compounds. Journal of Immunological Methods, 2021, 494, 113051.	0.6	2
7	Effect of acute total sleep deprivation on plasma melatonin, cortisol and metabolite rhythms in females. European Journal of Neuroscience, 2020, 51, 366-378.	1.2	47
8	De novo phosphatidylcholine synthesis is required for autophagosome membrane formation and maintenance during autophagy. Autophagy, 2020, 16, 1044-1060.	4.3	67
9	First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. Clinical Cancer Research, 2020, 26, 4777-4784.	3.2	31
10	Drug development. , 2020, , 159-199.		1
11	Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation. Metabolomics, 2020, 16, 50.	1.4	2
12	Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736. Blood Advances, 2020, 4, 1478-1491.	2.5	15
13	Preclinical Studies to Enable First in Human Clinical Trials. , 2020, , 45-69.		1
14	Design, Synthesis and Characterization of Covalent KDM5 Inhibitors. Angewandte Chemie, 2019, 131, 525-529.	1.6	1
15	Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers. Molecular Cancer Therapeutics, 2019, 18, 1396-1404.	1.9	14
16	International Ring Trial of a High Resolution Targeted Metabolomics and Lipidomics Platform for Serum and Plasma Analysis. Analytical Chemistry, 2019, 91, 14407-14416.	3.2	66
17	C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays. European Journal of Medicinal Chemistry, 2019, 177, 316-337.	2.6	12
18	Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology species. European Journal of Pharmaceutical Sciences, 2019, 139, 104899.	1.9	3

#	Article	IF	Citations
19	High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers. Molecular Cancer Therapeutics, 2019, 18, 1696-1707.	1.9	24
20	Design, Synthesis and Characterization of Covalent KDM5 Inhibitors. Angewandte Chemie - International Edition, 2019, 58, 515-519.	7.2	22
21	PIPA: A phase Ib study of selective ÃŸ-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancersâ€"Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.. Journal of Clinical Oncology, 2019, 37, 3087-3087.	0.8	4
22	Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4-d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N²-(2-Ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N⁸-neopentylpyrido[3,4-(BOS172722). Journal of Medicinal Chemistry, 2018, 61, 8226-8240.	2.9	24
23	Abstract 1651: In vitro and in vivo profile of the preclinical candidate and MPS1 kinase inhibitor CCT289346. , 2018, , .		0
24	Assessing histone demethylase inhibitors in cells: lessons learned. Epigenetics and Chromatin, 2017, 10, 9.	1.8	40
25	Interlaboratory Reproducibility of a Targeted Metabolomics Platform for Analysis of Human Serum and Plasma. Analytical Chemistry, 2017, 89, 656-665.	3.2	203
26	Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma. Molecular Cancer Therapeutics, 2017, 16, 2315-2323.	1.9	8
27	Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy. British Journal of Cancer, 2017, 116, 1166-1176.	2.9	23
28	Development and validation of a LCâ€"MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma. Bioanalysis, 2017, 9, 1001-1010.	0.6	7
29	Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen. Journal of Medicinal Chemistry, 2017, 60, 180-201.	2.9	47
30	Pyrido[3,4-d]pyrimidin-4(3H)-one metabolism mediated by aldehyde oxidase is blocked by C2-substitution. Xenobiotica, 2017, 47, 771-777.	0.5	6
31	An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors.. Journal of Clinical Oncology, 2017, 35, 2503-2503.	0.8	12
32	A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC.. Journal of Clinical Oncology, 2017, 35, 135-135.	0.8	3
33	A phase I trial of selective PI3K inhibitor taselisib (tas) plus palbociclib (palb) with and without endocrine therapy incorporating pharmacodynamic (PD) studies in patients (pts) with advanced cancers.. Journal of Clinical Oncology, 2017, 35, 2573-2573.	0.8	1
34	Abstract 4036: Induction of detrimental aneuploidy in basal breast cancer cells treated by MPS1 inhibitors in combination with paclitaxel. , 2017, , .		0
35	Abstract LB-304: Discovery of chemical probe CCT251236: An orally bioavailable efficacious pirin ligand from an HSF1 phenotypic screen. , 2017, , .		0
36	Abstract 193: Inhibitors of MPS1: Discovery of CCT289346, a highly potent, selective and orally available preclinical candidate. , 2017, , .		0

#	Article	IF	Citations
37	Abstract 129: Assessing the mechanism and therapeutic potential of modulators of the human mediator complex-associated protein kinases CDK8 and CDK19. , 2017, , .		0
38	Capillary Microsampling of Mouse Blood in Early Pre-Clinical Studies: A Preferred Alternative to Dried Blood Spot Sampling. Journal of Bioanalysis & Biomedicine, 2016, 08, .	0.1	2
39	Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases. ELife, 2016, 5, .	2.8	69
40	2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19. ACS Medicinal Chemistry Letters, 2016, 7, 573-578.	1.3	39
41	Synthesis and Evaluation of a 2,11â€Cembranoidâ€Inspired Library. Chemistry - A European Journal, 2016, 22, 5657-5664.	1.7	10
42	Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737). Journal of Medicinal Chemistry, 2016, 59, 5221-5237.	2.9	24
43	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach. Journal of Medicinal Chemistry, 2016, 59, 3671-3688.	2.9	29
44	Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation. Molecular Cancer Therapeutics, 2016, 15, 1412-1424.	1.9	16
45	Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening. Journal of Medicinal Chemistry, 2016, 59, 9337-9349.	2.9	86
46	The pharmacological audit trail (PhAT): Use of tumor models to address critical issues in the preclinical development of targeted anticancer drugs. Drug Discovery Today: Disease Models, 2016, 21, 23-32.	1.2	8
47	p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance. Cancer Research, 2016, 76, 3025-3035.	0.4	33
48	Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9. MedChemComm, 2016, 7, 1580-1586.	3.5	19
49	Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1443-1451.	1.0	34
50	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19. Journal of Medicinal Chemistry, 2016, 59, 1078-1101.	2.9	89
51	8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 1388-1409.	2.9	83
52	Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations. Cancer Research, 2016, 76, CT010-CT010.	0.4	11
53	Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. Oncotarget, 2016, 7, 57525-57544.	0.8	42
54	The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eî¼-MYC driven B-cell lymphoma. Oncotarget, 2016, 7, 2329-2342.	0.8	56

#	Article	IF	Citations
55	Abstract 3025: Discovery of preclinical development candidate inhibitors of the mediator complex-associated kinases CDK8 and CDK19 and evaluation of their therapeutic potential. , 2016, , .		1
56	First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Panâ€“Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 77-86.	3.2	265
57	Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen. Journal of Medicinal Chemistry, 2015, 58, 1717-1735.	2.9	65
58	Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. Cancer Cell, 2015, 27, 72-84.	7.7	165
59	Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B. Journal of Medicinal Chemistry, 2015, 58, 2553-2559.	2.9	90
60	A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nature Chemical Biology, 2015, 11, 973-980.	3.9	114
61	7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituent. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4203-4209.	1.0	13
62	Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients. Cancer Research, 2015, 75, CT323-CT323.	0.4	12
63	A first-in-human study of the dual ROCK I/II inhibitor, AT13148, in patients with advanced cancers.. Journal of Clinical Oncology, 2015, 33, 2566-2566.	0.8	5
64	Abstract 3642: Structure enabled design of inhibitors of the mitotic kinase MPS1. , 2015, , .		0
65	Effect of sleep deprivation on the human metabolome. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10761-10766.	3.3	394
66	First-in-human, first-in-class phase 1 study of a novel oral multi-AGC kinase inhibitor AT13148 in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, 2554-2554.	0.8	6
67	Abstract LB-201: MYC and TP53 defects interact at medulloblastoma relapse to define rapidly progressive disease and can be targeted therapeutically. , 2014, , .		0
68	Structure-Based Design of Orally Bioavailable 1H-Pyrrolo[3,2-c]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1). Journal of Medicinal Chemistry, 2013, 56, 10045-10065.	2.9	72
69	Aurora Isoform Selectivity: Design and Synthesis of Imidazo[4,5-b]pyridine Derivatives as Highly Selective Inhibitors of Aurora-A Kinase in Cells. Journal of Medicinal Chemistry, 2013, 56, 9122-9135.	2.9	70
70	Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo. Clinical Cancer Research, 2013, 19, 5940-5951.	3.2	124
71	The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design. Oncotarget, 2013, 4, 1647-1661.	0.8	20
72	Abstract 3517: Changes in plasma components of Î²-oxidation as a pharmacodynamic (PD) biomarker of PI3K inhibition by GDC-0941, a potent, pan-inhibitor of Class I phosphatidyl-inositol-3-kinase (PI3K).. , 2013, , .		0

#	Article	IF	Citations
73	Abstract 3242: CCT271850, a novel, selective, highly potent and orally bioavailable Mps1 kinase inhibitor.. , 2013, , .		0
74	CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs. Clinical Cancer Research, 2012, 18, 5650-5661.	3.2	84
75	A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors. Clinical Cancer Research, 2012, 18, 2687-2694.	3.2	66
76	Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1267-76.	3.3	31
77	AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity. Clinical Cancer Research, 2012, 18, 3912-3923.	3.2	86
78	Identification of Human Plasma Metabolites Exhibiting Time-of-Day Variation Using an Untargeted Liquid Chromatographyâ€“Mass Spectrometry Metabolomic Approach. Chronobiology International, 2012, 29, 868-881.	0.9	124
79	Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2012, 55, 8721-8734.	2.9	61
80	Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 10229-10240.	2.9	27
81	The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma. Cancer Cell, 2012, 22, 117-130.	7.7	270
82	A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Investigational New Drugs, 2012, 30, 341-349.	1.2	122
83	Abstract 928: The novel clinical candidate AT13148 is an oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity and demonstrates a mechanism of action distinct from AKT inhibitors. , 2012, , .		0
84	Abstract 1817: Characterisation of CCT251455, a novel, selective and highly potent Mps1 kinase inhibitor. , 2012, , .		0
85	Abstract 2501: Inhibition of the PI3K pathway potentiates temozolomide effects in pediatric glioblastoma and results in alterations in glucose and choline metabolism detected by MRS. , 2012, , .		0
86	Targeting the Hsp90 Molecular Chaperone with Novel Macrolactams. Synthesis, Structural, Binding, and Cellular Studies. ACS Chemical Biology, 2011, 6, 1339-1347.	1.6	27
87	The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and SensitizesMYCN-Amplified NeuroblastomaIn Vivo. Molecular Cancer Therapeutics, 2011, 10, 2115-2123.	1.9	79
88	Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors. Bioorganic and Medicinal Chemistry, 2011, 19, 6949-6965.	1.4	31
89	Structure-Based Design of Potent and Selective 2-(Quinazolin-2-yl)phenol Inhibitors of Checkpoint Kinase 2. Journal of Medicinal Chemistry, 2011, 54, 580-590.	2.9	46
90	Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing. Journal of Medicinal Chemistry, 2011, 54, 8328-8342.	2.9	48

#	Article	IF	Citations
91	Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements. Bioorganic and Medicinal Chemistry, 2011, 19, 836-851.	1.4	17
92	Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRÎ±/Î². Molecular Cancer Therapeutics, 2011, 10, 1407-1418.	1.9	45
93	A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors. Clinical Cancer Research, 2011, 17, 1561-1570.	3.2	178
94	Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930. Molecular Cancer Therapeutics, 2011, 10, 360-371.	1.9	65
95	Discovering and Developing PI3 Kinase Inhibitors for Cancer: Rapid Progress through Academic-Biotech-Pharma Interactions: Figure 1.. Molecular Cancer Therapeutics, 2011, 10, 2017-2018.	1.9	2
96	Abstract B74: The dual FLT3-Aurora inhibitor CCT241736 overcomes resistance to selective FLT3 inhibition driven by FLT3 ligand and FLT3 point mutations in acute myeloid leukemia.. , 2011, , .		3
97	Abstract 3554: CCT137690, a dual inhibitor of Aurora and FLT3 kinases, sensitizes FLT3-ITD positive acute myeloid leukemia and overcomes resistance to selective FLT3-inhibition. , 2011, , .		1
98	Abstract 2544: Preclinical pharmacodynamics (PD) of ONX 0801, a folate receptor-Î± (FRÎ±) and tumor-targeted thymidylate synthase (TS) inhibitor. , 2011, , .		0
99	Imidazo[4,5-b]pyridine Derivatives As Inhibitors of Aurora Kinases: Lead Optimization Studies toward the Identification of an Orally Bioavailable Preclinical Development Candidate. Journal of Medicinal Chemistry, 2010, 53, 5213-5228.	2.9	80
100	Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6657-6660.	1.0	7
101	Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy. Journal of Clinical Oncology, 2010, 28, 1481-1488.	0.8	369
102	Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic. Cancer Research, 2010, 70, 2146-2157.	0.4	254
103	A Useful Approach to Identify Novel Small-Molecule Inhibitors of Wnt-Dependent Transcription. Cancer Research, 2010, 70, 5963-5973.	0.4	96
104	The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase Î± Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy. Cancer Research, 2010, 70, 5507-5517.	0.4	58
105	The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106. Molecular Cancer Therapeutics, 2010, 9, 89-100.	1.9	77
106	Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt). Journal of Medicinal Chemistry, 2010, 53, 2239-2249.	2.9	68
107	Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor. Journal of Medicinal Chemistry, 2010, 53, 8663-8678.	2.9	74
108	Development of Novel, Highly Potent Inhibitors of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF): Increasing Cellular Potency through Optimization of a Distal Heteroaromatic Group. Journal of Medicinal Chemistry, 2010, 53, 2741-2756.	2.9	23

#	Article	IF	Citations
109	Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell Cycle, 2009, 8, 443-453.	1.3	69
110	Cross-platform Q-TOF validation of global exo-metabolomic analysis: Application to human glioblastoma cells treated with the standard PI 3-Kinase inhibitor LY294002â˜†. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 1352-1358.	1.2	26
111	Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3-d]pyrimidine Inhibitors of the Hsp90 Molecular Chaperone. Journal of Medicinal Chemistry, 2009, 52, 4794-4809.	2.9	157
112	Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Molecular Cancer Therapeutics, 2009, 8, 1725-1738.	1.9	253
113	Pyridoimidazolones as Novel Potent Inhibitors of v-Raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF). Journal of Medicinal Chemistry, 2009, 52, 2255-2264.	2.9	37
114	An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemotherapy and Pharmacology, 2008, 62, 769-778.	1.1	36
115	The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer. Journal of Medicinal Chemistry, 2008, 51, 5522-5532.	2.9	710
116	4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer. Journal of Medicinal Chemistry, 2008, 51, 196-218.	2.9	386
117	Identification of 4-(4-Aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as Selective Inhibitors of Protein Kinase B through Fragment Elaboration. Journal of Medicinal Chemistry, 2008, 51, 2147-2157.	2.9	93
118	Targeting the PI3Kâ€“AKTâ€“mTOR pathway: progress, pitfalls, and promises. Current Opinion in Pharmacology, 2008, 8, 393-412.	1.7	488
119	NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis. Cancer Research, 2008, 68, 2850-2860.	0.4	433
120	Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven. Journal of Clinical Oncology, 2008, 26, 4563-4571.	0.8	819
121	The Phosphoinositide-Specific Phospholipase C Inhibitor U73122 (1-(6-((17Î²-3-Methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione) Spontaneously Forms Conjugates with Common Components of Cell Culture Medium. Drug Metabolism and Disposition, 2007, 35, 1017-1022.	1.7	35
122	Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Molecular Cancer Therapeutics, 2007, 6, 1198-1211.	1.9	141
123	Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Molecular Cancer Therapeutics, 2007, 6, 3147-3157.	1.9	65
124	The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery. Molecular Cancer Therapeutics, 2007, 6, 428-440.	1.9	72
125	Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases. Cancer Research, 2007, 67, 5840-5850.	0.4	337
126	In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors. Cancer Research, 2007, 67, 2206-2216.	0.4	111

#	Article	IF	Citations
127	Application of Meso Scale Technology for the Measurement of Phosphoproteins in Human Tumor Xenografts. Assay and Drug Development Technologies, 2007, 5, 391-402.	0.6	49
128	Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110Î± inhibitors. Bioorganic and Medicinal Chemistry, 2007, 15, 403-412.	1.4	120
129	Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110Î± inhibitors. Bioorganic and Medicinal Chemistry, 2007, 15, 5837-5844.	1.4	112
130	Synthesis and biological evaluation of pyrido[3â€²,2â€²:4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110Î± inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2438-2442.	1.0	127
131	594: Abiraterone Acetate, an Oral Irreversible Inhibitor of CYP450C17, Administered to Castration Refractory Prostate Cancer Patients is Safe, Suppresses Androgen and Steroid Precursor Levels, and has a High Degree of Durable Antitumor Activity. Journal of Urology, 2007, 177, 199-199.	0.2	0
132	Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of the novel anticancer agent 17-DMAG in human plasma. Rapid Communications in Mass Spectrometry, 2006, 20, 2845-2850.	0.7	9
133	Drugging the PI3 kinome. Nature Biotechnology, 2006, 24, 794-796.	9.4	65
134	A validated liquid chromatographicâ€“tandem mass spectroscopy method for the quantification of abiraterone acetate and abiraterone in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 843, 262-267.	1.2	21
135	Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Molecular Cancer Therapeutics, 2006, 5, 187-196.	1.9	84
136	Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors. Molecular Cancer Therapeutics, 2006, 5, 1628-1637.	1.9	37
137	A liquid chromatographicâ€“tandem mass spectrometric method for the determination of two selective thymidylate synthase inhibitors, BGC945 and BGC638, in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 824, 181-188.	1.2	3
138	Identification of biliary metabolites of ifosfamide using 31P magnetic resonance spectroscopy and mass spectrometry. Cancer Chemotherapy and Pharmacology, 2005, 56, 409-414.	1.1	8
139	BGC 945, a Novel Tumor-Selective Thymidylate Synthase Inhibitor Targeted to Î±-Folate Receptorâ€“Overexpressing Tumors. Cancer Research, 2005, 65, 11721-11728.	0.4	94
140	Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies. Journal of Clinical Oncology, 2005, 23, 4152-4161.	0.8	479
141	In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202. Clinical Cancer Research, 2005, 11, 4875-4887.	3.2	127
142	Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Molecular Cancer Therapeutics, 2005, 4, 1521-1532.	1.9	205
143	Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models. Clinical Cancer Research, 2005, 11, 7023-7032.	3.2	170
144	Small Molecule Antagonists of the Ïƒ-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth in Vitro and in Vivo. Cancer Research, 2004, 64, 4875-4886.	0.4	164

#	Article	IF	Citations
145	Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice. Cancer Chemotherapy and Pharmacology, 2004, 54, 475-486.	1.1	24
146	Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. Molecular Cancer Therapeutics, 2004, 3, 353-62.	1.9	27
147	Validation of liquid chromatography assay for the quantitation of (Z)-3-[2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]propionic acid (SU006668) in human plasma and its application to a phase I clinical trial. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 785, 175-186.	1.2	2
148	Overexpression of BclXL in a human ovarian carcinoma cell line: Paradoxic effects on chemosensitivityin vitro versusin vivo. International Journal of Cancer, 2002, 97, 858-863.	2.3	17
149	Characterization of a Human Colorectal Carcinoma Cell Line with Acquired Resistance to Flavopiridol. Molecular Pharmacology, 2001, 60, 885-893.	1.0	19
150	Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkinâ€™s Lymphoma. Journal of Clinical Oncology, 2000, 18, 1812-1823.	0.8	434
151	Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. Journal of Inorganic Biochemistry, 1999, 77, 111-115.	1.5	197
152	Pharmacologic Disposition of a Phosphorothioate Oligodeoxynucleotide in Mice. Nucleosides & Nucleotides, 1997, 16, 1699-1702.	0.5	0
153	A Phase I/II Study of a 72-h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma. Sarcoma, 1997, 1, 149-154.	0.7	6
154	Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells. Biochemical Pharmacology, 1996, 51, 1293-1301.	2.0	48
155	Preclinical pharmacology of 1069C85, a novel tubulin binder. Cancer Chemotherapy and Pharmacology, 1994, 35, 169-173.	1.1	2
156	High-performance liquid chromatographic assay for the measurement of the novel microtubule inhibitor 1069C85 in biological tissues and fluids. Biomedical Applications, 1993, 622, 243-248.	1.7	3